Vitality Biopharma to Present at the 7th Annual LD Micro Invitational

ID: 1506379
recent pressrelease next pressrelease

(businesspress24) - LOS ANGELES, CA -- (Marketwired) -- 05/30/17 -- (OTCQB: VBIO) ("Vitality Biopharma", "Vitality", or the "Company") a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced that it will be presenting at the 7th Annual LD Micro Invitational in Los Angeles.

The corporate presentation is on Tuesday, June 6th at 9:00 AM PST / 12:00 PM EST. Mr. Robert Brooke, CEO of Vitality, will be giving the presentation and meeting with investors during the event. There will be a live webcast of Vitality''s presentation available here: .

Vitality''s presentation will include a corporate update and discuss recent scientific advances related to use of gut-targeted cannabinoids for treating pediatric inflammatory bowel disease, colorectal cancer, and C.difficile infections. Vitality''s prodrug technology is designed to enable targeted delivery of cannabinoids and may enable treatment of these conditions while reducing or eliminating drug psychoactivity.

(OTCQB: VBIO)
Vitality Biopharma is dedicated to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. For more information, visit: . Follow us on , and .

This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the United States Securities Act of 1933, as amended and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

1-530-231-7800



More information:
http://www.credenceresearch.com/report/consumer-electronics-market http://getwebsitetraffic.com.au/ http://www.realwire.com/releases/Egenera-Announces-the-Availability-of-Xterity-Cloud-Services-on-G-Cloud-9 http://www.pcbsino.com http://www.realwire.com/r



Keywords (optional):

stvf, vitality-biopharma, cannabinoids, neurological, inflammatory, disorders, ld-micro, investors,



Company information / Profile:

PressRelease by

Requests:



PressContact / Agency:



published by: Marketwired
print pressrelease  send to a friend  

Date: 05/30/2017 - 06:00
Language: English
News-ID 1506379
Character count: 3060
Kontakt-Informationen:
Firma: Vitality Biopharma, Inc.
Ansprechpartner: Feedback to businesspress24.com about Pressrelease-id:
Stadt: LOS ANGELES, CA
Telefon:

Meldungsart:
Versandart:
Freigabedatum:
Comments:



Number of hits: 198

Linking-Tips:



Direct Link to this PressRelease:






We would appreciate a link in your News-, Press- or Partner-Site.

Comments on this PressRelease






All members: 9 438
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 49


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.